Ischemic Heart Disease Clinical Trial
— CTO-PCIOfficial title:
Chronic Total Occlusion Percutaneous Coronary Intervention CTO-PCI Study
NCT number | NCT03988166 |
Other study ID # | ST2955 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 20, 2020 |
Est. completion date | February 22, 2021 |
Verified date | October 2021 |
Source | Vascular Solutions LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is to evaluate angiographic confirmation of placement of any guidewire beyond the CTO, in the true vessel lumen, in patients undergoing CTO percutaneous coronary intervention (PCI) in which at least one Teleflex guidewire and at least one Turnpike catheter are used.
Status | Completed |
Enrollment | 150 |
Est. completion date | February 22, 2021 |
Est. primary completion date | February 22, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Participants must meet all of the following inclusion criteria: General inclusion criteria 1. At least 18 years of age at the time of consent 2. Experiencing clinical symptoms considered suggestive of ischemic heart disease (e.g., chest pain or discomfort, heart failure) or has evidence of myocardial ischemia (e.g., abnormal functional study) attributed to the CTO target vessel and is scheduled for clinically indicated percutaneous revascularization 3. Participant is eligible and consents to undergo PCI procedure 4. Acceptable candidate for percutaneous transluminal coronary angioplasty (PTCA), stenting, and emergency coronary artery bypass grafting (CABG) 5. Willing and able to sign a study Informed Consent Form (ICF) approved by a local or central Institutional Review Board (IRB) 6. Female participants of childbearing potential must have a negative pregnancy test per standard of care for PCI and be practicing contraception Angiographic inclusion criteria 7. A minimum of one de novo lesion with at least one target segment in a native coronary vessel meeting the definition of CTO (any non-acute total coronary occlusion fulfilling the angiographic characteristics consistent with high-grade native coronary stenosis (Thrombolysis in Myocardial Infarction (TIMI) score of 0 or 1) and estimated to be in duration of = 3 months by clinical history and/or comparison with antecedent angiogram or electrocardiogram) Exclusion Criteria: Participants must not meet any of the following exclusion criteria: General exclusion criteria 1. History of allergy to iodinated contrast that cannot be effectively managed medically 2. Evidence of acute myocardial infarction (MI) within 72 hours prior to the intended treatment defined as creatine kinase-muscle brain subunits (CK-MB) greater than 3 times the upper limit of normal (ULN) 3. Previous coronary interventional procedure of any kind within 30 days prior to the procedure 4. Any contraindication to cardiac catheterization or to any of the standard concomitant therapies used during routine cardiac catheterization and PCI (e.g., aspirin, clopidogrel, unfractionated heparin) 5. Target lesion requires treatment with another device, after successful crossing with a study device, other than PTCA devices prior to stent placement 6. Atherectomy procedure is planned for the target lesion 7. Known history of clinically significant abnormal laboratory findings = 14 days prior to enrollment, including: - Neutropenia (<1000 neutrophils/mm^3) - Thrombocytopenia (<100,000 platelets/mm^3) - Aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase, or bilirubin > 1.5 × ULN - Serum creatinine >2.0 mg/dL 8. Evidence of current clinical instability including the following: - Sustained systolic blood pressure <100 mmHg or cardiogenic shock - Acute pulmonary edema or severe congestive heart failure (CHF). Severe CHF is defined as New York Heart Association (NYHA) Class IV - Suspected acute myocarditis, pericarditis, endocarditis, or cardiac tamponade - Suspected dissecting aortic aneurysm - Hemodynamically significant valvular heart disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy, or congenital heart disease 9. History of stroke or transient ischemic attack within 6 months prior to procedure 10. Active peptic ulcer or upper gastrointestinal bleeding within 6 months prior to procedure 11. History of bleeding diathesis or coagulopathy or refusal of blood transfusions 12. Other pathology such as cancer, known mental illness, etc., which might, in the opinion of the Investigator, put the patient at risk or confound the results of the study 13. Unable or unwilling to comply with the protocol 14. Currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints; or requires coronary angiography, intravascular ultrasound, or other coronary artery imaging procedures Angiographic exclusion criteria 15. Occlusion involves segment within previous stent ("in-stent occlusions") 16. Extensive lesion-related thrombus (TIMI thrombus grade 3 or 4) 17. Previous stenting (drug-eluting or bare metal) in the target vessel unless the following conditions are met: - It has been at least 9 months since the previous stenting - Target lesion is =15 mm away from the previously placed stent - Previously stented segment (stent plus 5 mm on either side) has no more than 40 percent diameter stenosis, based on visual estimate 18. Target vessel has other lesions proximal to the total occlusion identified with > 75 percent diameter stenosis based on visual estimate; exception: planned stenting of a lesion proximal to the target lesion that can be covered by a single stent (i.e., tandem lesions) is acceptable |
Country | Name | City | State |
---|---|---|---|
United States | Emory University | Atlanta | Georgia |
United States | Piedmont Heart Institute | Atlanta | Georgia |
United States | Beth Israel Deaconess Medical Center | Boston | Massachusetts |
United States | Brigham and Women's Hospital | Boston | Massachusetts |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | The Christ Hospital | Cincinnati | Ohio |
United States | Missouri Cardiovascular Specialists | Columbia | Missouri |
United States | Henry Ford Hospital | Detroit | Michigan |
United States | Minneapolis Heart Institute Foundation | Minneapolis | Minnesota |
United States | Columbia University Medical Center | New York | New York |
United States | NYU Langone Health | New York | New York |
United States | University of Washington | Seattle | Washington |
United States | Torrance Memorial Medical Center | Torrance | California |
Lead Sponsor | Collaborator |
---|---|
Vascular Solutions LLC | Bright Research Partners, Teleflex |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Procedure Success | Defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital major adverse cardiac events (MACE).
• MACE defined as any serious adverse experience that includes cardiac death, target lesion revascularization, or post-procedural myocardial infarction (MI) (Q-wave or non-Q-wave, with creatine kinase (CK) with Muscle (M)-Brain (B) subunits > 3 ULN). |
Through Discharge up to 24 hours post-procedure | |
Secondary | Number of Participants With Successful Recanalization. | Defined as angiographic confirmation of crossing the chronic total occlusion and restoring blood flow to the affected area. | Through Procedure, up to 4 hours | |
Secondary | Number of Participants With In-hospital MACE. | Defined as any serious adverse experience that includes cardiac death, target lesion revascularization, or post-procedural MI (Q-wave or non-Q-wave, with CK-MB > 3 ULN). The components of MACE will also be reported separately. | Through Discharge up to 24 hours | |
Secondary | Number of Participants With Clinically Significant Perforation. | Defined as any perforation resulting in hemodynamic instability and/or requiring intervention including pericardiocentesis, embolization, prolonged balloon occlusion, stent graft, or comparable therapy. | Through Procedure up to 4 hours | |
Secondary | Number of Participants With Procedural Success According to Crossing Technique. | Procedural success is defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital major adverse cardiac events (MACE). | Through Procedure up to 4 hours post-procedure | |
Secondary | Number of Participants With Technical Success. | Defined as successful guidewire recanalization is applicable to investigational devices as at least one investigational guidewire must be used in every procedure. | Through Procedure up to 4 hours post-procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Active, not recruiting |
NCT04562805 -
Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)
|
N/A | |
Recruiting |
NCT05292079 -
CAPTURER PMCF Study ( rEPIC04D )
|
||
Recruiting |
NCT05292014 -
ANGIOLITE PMCF Study ( rEPIC04F )
|
||
Recruiting |
NCT05292092 -
Essential Pro PMCF Study ( rEPIC04E )
|
||
Recruiting |
NCT05292118 -
Navitian PMCF Study ( rEPIC04C )
|
||
Completed |
NCT05292105 -
NC Xperience PMCF Study( rEPIC04B)
|
||
Completed |
NCT03076801 -
Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?
|
N/A | |
Not yet recruiting |
NCT04153383 -
Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
|
||
Recruiting |
NCT02729064 -
Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose
|
Phase 1 | |
Recruiting |
NCT02982434 -
The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation
|
Phase 2 | |
Completed |
NCT02468401 -
Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions
|
N/A | |
Completed |
NCT02759406 -
Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study
|
N/A | |
Recruiting |
NCT01681381 -
Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
|
N/A | |
Completed |
NCT01699802 -
Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa)
|
N/A | |
Completed |
NCT01604213 -
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01724567 -
Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training
|
N/A | |
Completed |
NCT01334268 -
RESOLUTE China RCT
|
N/A | |
Completed |
NCT02159235 -
Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD)
|
N/A |